Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Short Interest Up 167.4% in September

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the recipient of a large growth in short interest in September. As of September 30th, there was short interest totalling 25,400 shares, a growth of 167.4% from the September 15th total of 9,500 shares. Approximately 2.0% of the shares of the company are sold short. Based on an average daily volume of 10,800 shares, the short-interest ratio is currently 2.4 days.

Institutional Investors Weigh In On Creative Medical Technology

An institutional investor recently bought a new position in Creative Medical Technology stock. Virtu Financial LLC acquired a new stake in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 16,374 shares of the company’s stock, valued at approximately $85,000. Virtu Financial LLC owned about 1.21% of Creative Medical Technology as of its most recent SEC filing. Hedge funds and other institutional investors own 1.42% of the company’s stock.

Creative Medical Technology Stock Down 1.4 %

Shares of NASDAQ CELZ traded down $0.06 during trading on Friday, hitting $4.10. The company had a trading volume of 4,442 shares, compared to its average volume of 72,436. Creative Medical Technology has a 12 month low of $2.65 and a 12 month high of $10.28. The stock has a 50 day simple moving average of $3.27 and a 200 day simple moving average of $3.95.

Creative Medical Technology (NASDAQ:CELZ) last released its earnings results on Friday, August 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.27). The company had revenue of $0.01 million during the quarter. On average, equities research analysts predict that Creative Medical Technology will post -3.29 earnings per share for the current year.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.